Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Classification of calcium antagonists (CA) is presented. Results of the large clinical trials (STONE, STOP-Hypertension-2, ALLHAT, ASCOT-BPLA etc.) devoted to estimation of CA effects on the risk of cardiovascular complications are analyzed. The significant place of dihydropyridine CA in current guidelines on arterial hypertension and ischemic heart disease therapy is underlined. Results of a pilot study on comparison of two amlodipines (original Norvasc and generic Stamlo M) are discussed.

About the Authors

E. V. Shilova
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation

S. Y. Martsevich
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation


1. Pitt B. Diversity of calcium antagonists. Clinical Therapeutics. 1997; 19 Suppl.A:3–17.

2. Kleinbloesem C.H., Van Brummelen P., Danhof M. et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther. 1987; 41:26– 30.

3. Opie L. Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second generation agents. Cardiovasc Drugs Ther 1989;3:482- 97.

4. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.

5. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation 1991;84:2598-600.

6. Beller GA. Calcium antagonists in the treatment of Prinzmetal angina and unstable angina pectoris. Circulation, 1989; 80(s.6): 76-87.

7. Waters D, Theroux P, Szlachcic J., et al. Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem and verapamil in variant angina. Am J Cardiol 1981;48:123-30.

8. Марцевич С.Ю. Замедляющие пульс антагонисты кальция – роль в современной терапии сердечно-сосудистых заболеваний. РМЖ 2003;11(15):875-8.

9. Staesssen J., Ji-Guang Wang, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens. 2002;15:85S-93S.

10. Остроумова О.Д., Мамаев В.И., Абакумова Ю.Е. Изолированная систолическая артериальная гипертензия. Consilium medicum 2003;5(5):255-8.

11. Лазебник Л.Б., Комиссаренко И.А. Рекомендации по диагности- ке и лечению артериальной гипертонии у больных старших воз- растов. РМЖ 2003;11(14):793-8.

12. Schulman SP, et al. The effects of antihypertensive therapy on lest ventricular mass in elderly patients. N Engl J Med 1990;322:1350-6.

13. Nalbantgil I, Onder R, Killiçcioglu B, et al. The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. Blood Press. 1996;5(5):285-91

14. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996;14:1237-45.

15. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SystEur) Trial Investigators. Lancet. 1997;350:757-64.

16. Wang JG, Liu G, Wang X, et al. Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens 1996; 10: 735-42.

17. Johannesson M, Dahlof B, Lindholm LH, et al. The cost-effectiveness of treating hypertension in elderly people – an analysis of the Swedish Trial in Old Patients with Hypertension (STOP- Hypertension). J Intern Med 1993; 234:317-23.

18. Hansson L., Lindholm L., Ekbom T., et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality. The Swedish Trial in Old Patients with Hypertension-II Study. Lancet 1999; 354: 1751-6.

19. Catapano A.L. Calcium antagonists and atherosclerosis. Experimental evidence. Eur. Heart J. 1997;18 Suppl A: A80 – A86.

20. Triggle DJ. Mechanisms of action of calcium channel antagonists. In: Calcium antagonists in clinical medicine. Ed. by M. Epstein, Philadelphia, 1998: 1-26.

21. Lichtlen P.R., Hugenholtz P.G., Rafflenbeul W., et al., on behalf of the INTACT group investigators. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990; 335: 1109– 13.

22. Brown M.J., Palmer C.R., Castaigne A., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.

23. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. JAMA 1993;270:713-24.

24. Метелица В.И. Новое в лечении хронической ишемической бо- лезни сердца. М., 1999.

25. Deanfield J., Detry J.M., Lichtlen P.R. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind circadian anti-ischemia program in Europe (CAPE Trial). J Am Coll Cardiol. 1994;24:1460-7.

26. Staesssen J., Ji-Guang Wang, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens. 2002;15:85S-93S.

27. Packer M., O’Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.

28. Rumiantsev DO, Piotrovskii VK, Metelitsa VI, et al. Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy. Br J Clin Pharmacol. 1989;28(3):357-61.

29. Rehnqvist N., Hiemdahl A., Billing E., et al. Effects of metoprolol us verapamil in patients with stable angina pectoris. The angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76-81.

30. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17:104-12.

31. Pitt B., Byington R., Furberg C. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102:1503-10.

32. Задионченко В.С., Кузьмичева Н.В., Свиридов А.А., и др. Клини- ко-функциональные особенности артериальной гипертонии при хроническом бронхообструктивном синдроме. Тер арх. 2000;(1):51–5

33. Задионченко В.С., Волкова Н.В., Свиридов А.А. и др. Антагонисты кальция в лечении системной и вторичной легочной артериаль- ной гипертонии. Клин фарм тер 1998;(4):32-6.

34. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981-97.

35. Dahlof B, Sever P, Poulter N at al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10-16;366:895-906.

36. Pahor M., Psaty B., Alderman M. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet 2000;356:1949-54.

37. Nissen S.E., Tuzcu E.M., Libby P. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-26.

38. An open-label randomized pharmacokinetic study to determine the bioequivalence and the effect of food on oral amlodipine formulations in healthy volunteers. Final report, 2001.

For citation:

Shilova E.V., Martsevich S.Y. DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES. Rational Pharmacotherapy in Cardiology. 2008;4(2):53-57. (In Russ.)

Views: 441

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)